Predictors of recurrent venous thromboembolism and bleeding on anticoagulation

Thrombosis Research

Volumn 140, Issue , 2016, Pages S93-S98

  Menapace, Laurel A ^a   McCrae, Keith R ^a   Khorana, Alok A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Bleeding; Cancer; Recurrent thromboembolism; Risk factors; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; D DIMER; LOW MOLECULAR WEIGHT HEPARIN; PADGEM PROTEIN; PROTHROMBIN; SELECTIN; THROMBOPLASTIN; TINZAPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BREAST CANCER; CANCER ASSOCIATED RECURRENT VENOUS THROMBOEMBOLISM; CANCER PATIENT; CANCER STAGING; CARDIOVASCULAR RISK; DEEP VEIN THROMBOSIS; HIGH RISK PATIENT; HUMAN; IMMOBILITY; KIDNEY FAILURE; LUNG CANCER; LUNG EMBOLISM; METASTASIS; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENT DISEASE; SOLID TUMOR; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; COMPLICATION; NEOPLASM; RISK FACTOR;

ANTICOAGULANTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; RECURRENCE; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84962909309     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(16)30106-2     Document Type: Article

References (30)

1. J.W. Blom, C.J. Doggen, S. Osanto, and F.R. Rosendaal Malignancies, prothrombotic mutations, and the risk of venous thrombosis JAMA 293 2005 715 722
2. G.C. Connolly, L.A. Menapace, T.R. Sousou, S. Safadjou, C.W. Francis, and A.A. Khorana Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients Clinical Lung Cancer 14 6 2013 713 718
3. L.A. Menapace, D.R. Peterson, A. Berry, T. Sousou, and A.A. Khorana Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer Thrombosis Haemostasis 106 2 2011 371 378
4. A.A. Khorana Venous thromboembolism and prognosis in cancer Thrombosis Research 125 6 2010 Jun 490 493
5. N. Levitan, A. Dowlati, S.C. Remick, and et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data Medicine (Baltimore) 78 1999 285 291
6. A.Y.Y. Lee, M.N. Levine, R.I. Baker, C. Bowden, A.K. Kakkar, M. Prins, F.R. Rickles, J.A. Julian, S. Haley, M.J. Kovacs, and M. Gent Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med. 349 2003 146 153
7. G. Meyer, Z. Marjanovic, J. Valcke, B. Lorcerie, Y. Gruel, P. Solal-Celigny, C. Le Maignan, J.M. Extra, P. Cottu, and D. Farge Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study Arch Intern Med. 162 2002 1729 1735
8. P. Prandoni, A.W. Lensing, A. Piccioli, E. Bernardi, P. Simioni, B. Girolami, and et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 100 2002 3484 3488
9. A.A. Khorana, N.M. Kuderer, E. Culakova, G.H. Lyman, and C.W. Francis Development and validation of predictive model for chemotherapy-associated thrombosis Blood 111 2008 4902 4907
10. M.L. Louzada, H. Majeed, V. Dao, and P.S. Wells Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies Blood Coagulation Fibrinolysis 22 2011 86 91
11. A.Y. Lee, M.N. Levine, R.I. Baker, C. Bowden, A.K. Kakkar, M. Prins, and et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) Investigators. Low molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med 349 2003 146 153
12. J. Trujillo-Santos, J.A. Nieto, G. Tiberio, A. Piccioli, P. Di Micco, P. Prandoni, M. Monreal, and RIETE Investigators Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry Thrombosis Haemostasis 100 3 2008 Sep 435 439
13. A.Y. Lee, P.W. Kamphuisen, G. Meyer, R. Bauersachs, M.S. Janas, M.F. Jarner, A.A. Khorana, and CATCH Investigators Tinzaparin versus Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial JAMA 314 7 2015 Aug 18 677 686
14. M.L. Louzada, M. Carrier, A. Lazo-Langner, V. Dao, M.J. Kovacs, T.O. Ramsay, and et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism Circulation 126 2012 448 454
15. Khorana AA, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Lee AY. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: The CATCH study. The American Society of Oncology Annual Meeting 2015.
16. I. Pabinger, J. Thaler, and C. Ay Biomarkers for prediction of venous thromboembolism in cancer Blood 122 2013 2011 2018
17. Khorana AA, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Lee AY and on behalf of the CATCH Investigators. Tissue factor (TF) as predictor of recurrent venous thromboembolism (VTE): risk factor and biomarker analysis from the catch trial of treatment of cancer associated VTE with tinzaparin or warfarin. ISTH Abstracts 2015.
18. M.A. Rodger, S.R. Kahn, P.S. Wells, D.A. Anderson, I. Chagnon, G. Le Gal, and et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy CMAJ 179 2008 417 426
19. S. Eichinger, G. Heinze, L.M. Jandeck, and P.A. Kyrle Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model Circulation 121 2010 1630 1636
20. A. Tosetto, A. Iorio, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger, and et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism. A proposed prediction score (DASH) J Thromb Haemost 10 2012 1019 1025
21. P.L. Den Exter, J. Kooiman, and M.V. Huisman Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis J Thromb Haemost 11 2013 998 1000
22. S. Ahn, K. Lim, Y. Lee, and J.L. Lee Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score Support Care Cancer 21 8 2013 Aug 2309 2313
23. C. Kearon, J.S. Ginsberg, M.J. Kovacs, and et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism N Engl J Med 349 2003 631 639
24. S. Schulman, R.J. Beyth, and C. Kearon Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edn) Chest 133 Suppl 2008 257S 298S
25. Khorana AA, Dalal, M., Lin, J, Connolly, GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer, 119: 648-655.
26. Kamphuisen PW, Lee AY, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA and on behalf of the CATCH Investigators. Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism - the CATCH study. ISTH Abstracts 2015.
27. G. Gussoni, S. Frasson, M. La Regina, P. Di Micco, and M. Monreal RIETE Investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry Thromb Haemost 100 1 2008 Jul 26 31
28. P.M. Kuijer, B.A. Hutten, M.H. Prins, and et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism Arch lntern Med 159 1999 457 460
29. W. Ageno, A.S. Gallus, and A. Wittkowsky Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 Suppl 2012 e44S e88S
30. H.K. Nieuwenhuis, J. Albada, and J.D. Banga Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin Blood 78 1991 2337 2343